In an effort to provide Alzheimer's and schizophrenia patients with better, safer medicines, biotech and big pharma have embarked on drug discovery programs targeting multiple cognitive mechanisms. Several of the resulting medications have progressed to late-stage clinical development. For patients suffering from these diseases, the new drugs have the potential to improve cognitive function over a longer term than available treatments, which fade in effectiveness over time.rnGiven the leaky and lucrative electronic trade in prescription drugs, it's likely that these medicines will be available to healthy people who hope to benefit from them as well.
展开▼
